Indoco Remedies gets USFDA nod to market Lofexidine tablets with 180 days exclusivity
Indoco Remedies Ltd has received final approval from the USFDA to market its generic Lofexidine tablets, used in opioid discontinuation treatment. The approval grants Indoco 180 days of Competitive Generic Therapy (CGT) exclusivity.
Drugmaker Indoco Remedies Ltd on Wednesday said it has received final approval from the US health regulator to market its generic Lofexidine tablets, used in opioid discontinuation treatment, with 180 days of competitive generic therapy exclusivity. The approval by the US Food and Drug Administration (USFDA) is for Lofexidine tablets 0.18 mg, a generic equivalent of Lucemyra tablets, 0.18 mg of USWM, LLC, Indoco Remedies said in a regulatory filing.
"Indoco has been granted a Competitive Generic Therapy (CGT) designation by the USFDA and being the first approved generic, is eligible for 180 days of CGT exclusivity for Lofexidine tablets, 0.18 mg in the USA," it added. This exclusivity will begin to run from the date of the first commercial marketing of the product. Indoco intends to launch the product immediately in the US, the company said.
The USFDA designates a drug with inadequate generic competition as a CGT."...This strengthens our position in the US market, driving us closer to expanding our reach in the US," Indoco Remedies Managing Director Aditi Panandikar said on the development. The product will be manufactured by Indoco at its manufacturing facility in Verna, Goa, the company said.
This product is indicated for the mitigation of symptoms associated with acute withdrawal from opioids and for the facilitation of the completion of opioid discontinuation treatment. Citing IQVIA Health data, the company said sales of the product are around USD 15.59 million with an expected growth of 38 percent.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Retirement Planning: SIP+SWP combination; Rs 15,000 monthly SIP for 25 years and then Rs 1,52,000 monthly income for 30 years
Top Gold ETF vs Top Large Cap Mutual Fund 10-year Return Calculator: Which has given higher return on Rs 11 lakh investment; see calculations
Retirement Calculator: 40 years of age, Rs 50,000 monthly expenses; what should be retirement corpus and monthly investment
SBI 444-day FD vs Union Bank of India 333-day FD: Know maturity amount on Rs 4 lakh and Rs 8 lakh investments for general and senior citizens
EPF vs SIP vs PPF Calculator: Rs 12,000 monthly investment for 30 years; which can create highest retirement corpus
Home loan EMI vs Mutual Fund SIP Calculator: Rs 70 lakh home loan EMI for 20 years or SIP equal to EMI for 10 years; which can be easier route to buy home; know maths
04:49 PM IST